To include your compound in the COVID-19 Resource Center, submit it here.

AnaptysBio left with slimmer pipeline after eczema candidate fails Phase IIb

AnaptysBio lost over $700 million in market cap Friday after reporting that IL-33 inhibitor etokimab, which it had hoped would compete with blockbuster inflammatory disease drug Dupixent, missed the primary endpoint in a trial to treat atopic dermatitis. The failure leaves the company with a slimmer in-house clinical pipeline that

Read the full 500 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE